No Data
No Data
Synaptogenix | 10-K: FY2024 Annual Report
Sector Update: Health Care Stocks Advance in Afternoon Trading
Synaptogenix Shares Jump After Board Forms Special Committee to Explore Strategic Opportunities
Synaptogenix Restructures Leadership Amid Strategic Refocus
Express News | Synaptogenix Inc: Delivery of a Termination Notice Pursuant to Its Agreement to Conduct a Phase 1 Trial of Bryostatin-1 in Multiple Sclerosis
Express News | Synaptogenix Inc - CEO Alan Tuchman's Salary Reduced to $12,500 per Month